Stifel Financial Corp Boosts Position in REGENXBIO Inc. (NASDAQ:RGNX)

Stifel Financial Corp lifted its position in shares of REGENXBIO Inc. (NASDAQ:RGNX) by 13.3% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 149,280 shares of the biotechnology company’s stock after purchasing an additional 17,563 shares during the quarter. Stifel Financial Corp owned about 0.30% of REGENXBIO worth $1,566,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors also recently bought and sold shares of the business. Maryland State Retirement & Pension System boosted its stake in REGENXBIO by 7.2% during the 2nd quarter. Maryland State Retirement & Pension System now owns 15,800 shares of the biotechnology company’s stock valued at $185,000 after purchasing an additional 1,067 shares during the last quarter. Amalgamated Bank raised its stake in REGENXBIO by 9.9% during the 2nd quarter. Amalgamated Bank now owns 13,613 shares of the biotechnology company’s stock worth $159,000 after acquiring an additional 1,227 shares during the period. FMR LLC raised its holdings in REGENXBIO by 166.8% during the third quarter. FMR LLC now owns 2,649 shares of the biotechnology company’s stock valued at $28,000 after acquiring an additional 1,656 shares during the period. Arizona State Retirement System raised its position in shares of REGENXBIO by 20.6% during the second quarter. Arizona State Retirement System now owns 11,669 shares of the biotechnology company’s stock valued at $137,000 after buying an additional 1,997 shares during the last quarter. Finally, nVerses Capital LLC grew its position in shares of REGENXBIO by 183.3% during the third quarter. nVerses Capital LLC now owns 3,400 shares of the biotechnology company’s stock valued at $36,000 after purchasing an additional 2,200 shares in the last quarter. 88.08% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on the company. Chardan Capital reaffirmed a “buy” rating and issued a $52.00 price objective on shares of REGENXBIO in a research note on Wednesday, November 20th. Raymond James reaffirmed an “outperform” rating and issued a $18.00 price objective on shares of REGENXBIO in a research note on Thursday, October 10th. Royal Bank of Canada reiterated an “outperform” rating and issued a $35.00 target price on shares of REGENXBIO in a report on Wednesday, December 11th. StockNews.com raised REGENXBIO from a “sell” rating to a “hold” rating in a research report on Friday, September 20th. Finally, HC Wainwright dropped their target price on shares of REGENXBIO from $40.00 to $36.00 and set a “buy” rating on the stock in a research report on Thursday, November 21st. Two investment analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $35.27.

Insider Buying and Selling

In other news, Director Argeris N. Karabelas sold 10,000 shares of the company’s stock in a transaction dated Tuesday, October 1st. The shares were sold at an average price of $10.11, for a total value of $101,100.00. Following the completion of the sale, the director now directly owns 11,286 shares of the company’s stock, valued at approximately $114,101.46. This represents a 46.98 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 13.13% of the stock is owned by company insiders.

REGENXBIO Stock Performance

Shares of RGNX opened at $7.62 on Friday. REGENXBIO Inc. has a 1 year low of $7.21 and a 1 year high of $28.80. The stock has a 50-day simple moving average of $9.58 and a 200-day simple moving average of $11.19. The stock has a market capitalization of $377.53 million, a PE ratio of -1.51 and a beta of 1.24.

REGENXBIO Company Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.